DDInter456 DDInter364
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Chlorpropamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Cyclophosphamide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Chlorpropamide
Cyclophosphamide {u} (Compound) causes {v} (Side Effect) Water retention
Water retention {u} (Side Effect) is caused by {v} (Compound) Chlorpropamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Cyclophosphamide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Probenecid
Probenecid {u} (Compound) resembles {v} (Compound) Chlorpropamide
Cyclophosphamide {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Chlorpropamide (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Chlorpropamide (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Chlorpropamide (Compound)
Cyclophosphamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Chlorpropamide (Compound)
Cyclophosphamide (Compound) causes Water retention (Side Effect) and Water retention (Side Effect) is caused by Chlorpropamide (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide (Compound) resembles Chlorpropamide (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Chlorpropamide (Compound)
Cyclophosphamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Probenecid (Compound) and Probenecid (Compound) resembles Chlorpropamide (Compound)
Cyclophosphamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)